Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Breelyn Wilky, MD
Study ID
Protocol Number: 22-0611
More information available at ClinicalTrials.gov: NCT04595747
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers